Introduction: The aim of this study was to determine and quantify the mechanisms responsible for the delays in bladder cancer diagnosis and initial treatment.

Material And Methods: Patients referred to two academic hospitals in Poland with a primary bladder tumor were prospectively identified and structurally interviewed. For all patients, time intervals between symptom onset, diagnostic and therapeutic interventions were assessed.

Results: A total of 144 patients diagnosed with bladder cancer were included in the analysis. The median time from symptom onset to treatment was 112 days. This comprised of the following median waiting times: 1) patient waiting time of 13 days, 2) assessment waiting time of 14 days and 3) treatment waiting time of 42 days. In the multivariate analysis, large city residence (OR 0.2, 95% CI 0.1-0.6) and comorbidity (OR 0.3, 95% CI 0.1-0.8) reduced the risk of delay, whereas medium-sized city residence (OR 1.4, 95% CI 0.4-5.1) and general practitioner as the first medical professional contact (OR 5.3, 95% CI 0.6-50.0) increased the risk of delay.

Conclusions: Diagnostic and treatment waiting times for bladder cancer in Poland are unsatisfactory. Potential solutions for shortening these delays include healthcare policy changes such as utilization of the oncological priority programs, primary care education and public health campaigns.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407782PMC
http://dx.doi.org/10.5173/ceju.2020.0158DOI Listing

Publication Analysis

Top Keywords

bladder cancer
16
waiting time
12
time days
12
diagnostic treatment
8
primary bladder
8
cancer poland
8
symptom onset
8
waiting times
8
treatment waiting
8
city residence
8

Similar Publications

Background: The role of repeat transurethral resection of bladder tumor (TURBT) for the management of nonmuscle invasive bladder carcinoma is debated, especially when initial resections include detrusor muscle. This study compares immediate second resection (additional deep biopsies in the same session) with standard restage TURBT performed 2-6 weeks post-initial TURBT to determine adequacy in detrusor muscle sampling and compare the disease rate at restage TURBT in both groups.

Material And Methods: A randomized trial was conducted at a tertiary care hospital, including patients aged ≥18 years undergoing TURBT with complete primary tumor resection.

View Article and Find Full Text PDF

Background And Objective: Research into new noninvasive diagnostic tools for bladder cancer (BCa) with superior sensitivity and specificity to cystoscopy and cytology is promising. The current study evaluated a diagnostic panel of tumor progression-related mRNAs in urine samples of NMIBC patients and controls.

Methods: This study carefully selected 129 participants, including 67 NMIBC patients, 31 hematuria patients due to nonmalignant urological disorders, and 31 healthy individuals.

View Article and Find Full Text PDF

[Impacts of curcumin on proliferation, migration and cisplatin resistance of bladder cancer cells by regulating LKB1-AMPK-LC3 signaling pathway].

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi

January 2025

National Key Laboratory of Bioreactors, School of Biological Engineering, East China University of Science and Technology, Shanghai 200237, China. *Corresponding author, E-mail:

Article Synopsis
  • The study investigates how curcumin affects bladder cancer cells regarding growth, movement, and resistance to cisplatin (a chemotherapy drug) by targeting a specific signaling pathway (LKB1-AMPK-LC3).
  • Human bladder cancer cells (T24) and their cisplatin-resistant counterparts (T24/DDP) were treated with varying concentrations of curcumin, and various assays measured cell proliferation, migration, autophagy, and apoptosis.
  • Results showed that curcumin, especially when combined with metformin, influences these cellular functions and could reduce drug resistance, affecting the expression of proteins in the targeted signaling pathway.
View Article and Find Full Text PDF

Urachal cancer, a rare malignancy, generally presents in the clinical setting with advanced stages of disease. Systemic treatment with chemotherapy is generally utilized in this setting. However, there remains a paucity of data on the effectiveness of immune checkpoint inhibitors or targeted therapies for urachal cancer.

View Article and Find Full Text PDF

Family caregivers play a vital role during the home care of urostomy patients by providing direct care and support. The role of family caregivers may extend to several years, even over ten years, in certain cases. In this process, the caregivers are impacted in various ways due to the patient's conditions and may not be able to identify and address their own needs, which often get ignored and remain unfulfilled.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!